Table 2.
Adjusteda hospitalization and mortality percentages of FMCHP patients with ONS and FMCHP patients without ONS at 1 year, among patients with indication to receive ONS (analyses based on ONS use)
| Hospitalizationb | Mortalityc | |
|---|---|---|
| FMCHP patients who received ONS with average serum albumin <3.8 g/dl within 2 mo of enrollment (n=235) | 68.4 (60.6, 74.7) | 12.7 (0.0, 44.7) |
| FMCHP patients who did not receive ONS with average serum albumin <3.8g/dl within 2 mo of enrollment (n=160) | 88.7 (75.3, 94.8) | 20.5 (0.0, 63.6) |
Data are expressed as percentages (95% confidence intervals). FMCHP, Fresenius Medical Care Health Plan; ONS, oral nutritional supplements.
Adjusted for age at enrollment, race, Hispanic ethnicity, years since ESRD onset at enrollment, diabetes as a comorbidity, FMCHP risk score category, and catheter as vascular access.
P<0.01. Significant differences between the survival estimates for patients with ONS and patients without ONS were tested using a z test.
P=0.76. Significant differences between the survival estimates for patients with ONS and patients without ONS were tested using a z test.